Overview
Alamar Biosciences is a proteomics company providing ultra-sensitive protein biomarker detection platforms for early disease detection and precision health research. The company's NULISA technology and ARGO HT system enable attomolar-level sensitivity with up to 12-log dynamic range for multiplexed protein analysis from liquid biopsies. Their applications span early-stage discovery, translational research, and clinical diagnostics, with particular focus on neurological and inflammatory biomarker detection.
Frequently asked questions
- What is Alamar's core technology platform?
- Alamar's proprietary NULISA Platform combined with the ARGO HT System delivers single-digit attomolar detection sensitivity for protein biomarkers. The platform enables highly multiplexed protein analysis from 25 µl liquid biopsy specimens with unprecedented breadth and depth, surpassing conventional immunoassays in sensitivity.
- What biomarkers and disease areas does Alamar focus on?
- Alamar specializes in brain-derived protein biomarkers and CNS applications, including assays for Alzheimer's disease detection, nerve regeneration, and inflammation markers. The company has launched multiplex CNS panels and brain-specific assays that detect biomarkers in blood previously only measurable in cerebrospinal fluid.
- What is Alamar's commercial status and revenue?
- Alamar Biosciences is a privately held company founded in 2018, based in Fremont, CA. The company filed for a $100 million IPO and reported $74 million in revenue for the 12 months ended December 31, 2025.
- What partnerships and collaborations has Alamar established?
- Alamar has strategic collaborations with Human Longevity, Inc. for longevity and precision health applications, and with SciLifeLab for advancing disease understanding through proteomics research and integration with the Human Protein Atlas.
- What applications does Alamar's technology support?
- Alamar's platform supports applications ranging from early-stage biomarker discovery and translational research to clinical diagnostics. The technology enables researchers and biopharmaceutical companies to interrogate the proteome with high-throughput precision for drug development and disease detection.